PXL01 program entering Phase III clinical trial

A biotech with global reach

Therapeutic peptides for bioactive wound care

Two first-in-category product candidates

New medical concept with extraordinary safety

Strategic partnerships in EU, Asia and USA

Innovative treatments for local administration

Press releases

October 1, 2018Promore Pharma has enrolled first patient in HEAL LL-37 in Poland
September 6, 2018Promore Pharma has conducted Investigator Meeting for HEAL LL-37 in Poland
September 3, 2018Promore Pharma Plans to Expand Indications of Therapeutic Peptide PXL01 in the Field of Dermal Scarring
August 22, 2018Promore Pharma receives approval for Phase IIb trial with LL-37 in Poland

More Press Releases

Interim report January – June 2018

Promore Pharma AB (publ) published its interim report for the second quarter 2018 on August 20, 2018.

Read the report

Calendar

November 21, 2018Redeye Life Science Seminar
November 23, 2018Interim report January – September 2018
February 26, 2019Year-end report 2018

More Events

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company’s aim is to develop two first-in-category products for indications with very few efficacious prescription pharmaceuticals, addressing high unmet medical need.

Vision

Promore Pharmas vision is to help patients with high medical needs in the area of bioactive wound care, through the development of products that strengthen and accelerate the body’s natural healing processes.

Market

Within the global wound care market Promore Pharma’s product candidates are intended for the bioactive wound care segment. The bioactive wound care segment constitutes the fastest growing segment within the overall wound care market with a projected annual growth rate from 2015-2020 of 14 percent and is expected to reach USD 7.3 billion in 2020.